FLAP inhibitors for the treatment of inflammatory diseases
Leukotrienes are lipid inflammatory mediators that are implicated in asthma, COPD, arthritis, cardiovascular disease and cancer. Leukotriene synthesis requires 5-lipoxygenase activating protein (FLAP), which acts as a scaffolding protein for the assembly of other enzymes involved in the leukotriene...
Main Author: | Sampson, A.P (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
2009-11.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
by: Heng Li, et al.
Published: (2018-10-01) -
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
by: Datong Zhang, et al.
Published: (2021-08-01) -
TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases
by: Juliane Totzke, et al.
Published: (2020-09-01) -
The Use of Flaps and Grafts in the Treatment of Urethral Stricture Disease
by: Eric S. Wisenbaugh, et al.
Published: (2015-01-01) -
Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases
by: Vincent Lagente, et al.
Published: (2005-03-01)